Antithrombotic therapy in valvular heart disease

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Patients with valvular heart disease (VHD) are at increased risk for thrombo-emboligenic events and often require antithrombotic therapy. This needs to be clearly weighted against the bleeding risk as this is often also increased. This chapter will provide an overview of current evidence available in patients with VHD. We will discuss general indications of antithrombotic therapy, its duration, dose, bridging during procedures and treatment options during pregnancy.

Original languageEnglish
Title of host publicationHeart Valve Disease
Subtitle of host publicationState of the Art
PublisherSpringer International Publishing AG
Number of pages12
ISBN (Electronic)9783030231040
ISBN (Print)9783030231033
Publication statusPublished - 1 Jan 2019


  • Antithrombotic therapy
  • Bridging
  • Endocarditis
  • Indications
  • Native VHD
  • Pregnancy
  • Prosthetic VHD
  • Rheumatic VHD
  • Valvular thrombosis


Dive into the research topics of 'Antithrombotic therapy in valvular heart disease'. Together they form a unique fingerprint.

Cite this